Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Employees - 4, CEO - Kevin A. Richardson II, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -49.35, Piotroski Score(max is 10): 3, Working Capital: $-1654283, Total Assets: $3962673, Retained Earnings: $-127393162, EBIT: -6290734, Total Liabilities: $5614956, Revenue: $2237344

AryaFin Target Price - $3.24 - Current Price $ - Analyst Target Price $